Holen Sie sich die Stockscreener-App
0.2983
3.15%
-0.0097
Schlusskurs vom Vortag:
$0.308
Offen:
$0.2952
24-Stunden-Volumen:
506.79K
Relative Volume:
0.48
Marktkapitalisierung:
$18.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.83M
KGV:
-0.3776
EPS:
-0.79
Netto-Cashflow:
$-20.87M
1W Leistung:
+1.02%
1M Leistung:
-7.13%
6M Leistung:
-37.59%
1J Leistung:
-86.44%
1-Tages-Spanne:
$0.2904
$0.3068
1-Wochen-Bereich:
$0.29
$0.3221
52-Wochen-Spanne:
$0.2223
$2.535
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2403 SIDNEY STREET, PITTSBURGH
Vergleichen Sie CGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.2983 | 18.31M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
Two Sigma Investments LP Boosts Stock Position in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
Cognition Therapeutics (CGTX) Secures Donation to Support Dement - GuruFocus
Cognition Therapeutics Launches Expanded Access Program for Zervimesine - TipRanks
Cognition Therapeutics Announces Expanded Access Program for Dementia with Lewy Bodies, Led by Dr. James Galvin - Nasdaq
Philanthropic Donor Funds Cognition Therapeutics’ Expanded - GlobeNewswire
Major Breakthrough: Donor Funds New Treatment Access for Lewy Body Dementia Patients - Stock Titan
B. Riley Expects Reduced Earnings for Cognition Therapeutics - Defense World
HC Wainwright Issues Positive Forecast for CGTX Earnings - Defense World
Alzheimer's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com
Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World
Cognition Therapeutics Releases New Episode of - GlobeNewswire
Lewy Body Dementia Caregivers Share Powerful Stories Alongside Leading Neurologists in New Medical Podcast - Stock Titan
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies - GlobeNewswire
CGTX: HC Wainwright & Co. Lowers Price Target While Maintaining Buy Rating | CGTX Stock News - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Exp - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Expected Equity Dilution | CGTX Stock News - GuruFocus
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Chardan Capital Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World
Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down - Nasdaq
Cognition announces outcomes from trial of zervimesine for geographic atrophy - Yahoo Finance
Cognition Therapeutics Inc (NASDAQ: CGTX) Stock Price Forecast: $100 - Stocksregister
Cognition Therapeutics Reports Promising Preclinical Data for Zervimesine in Protecting RPE Cells from Dry AMD at ARVO 2025 - Nasdaq
Cognition Therapeutics Presented Data at Association for - GlobeNewswire
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - Stock Titan
zervimesine shows promise in dry AMD trial - Investing.com
Cognition Therapeutics Reports Q1 2025 Financials and Progress - TipRanks
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics - Ophthalmology Times
zervimesine shows promise in dry AMD trial By Investing.com - Investing.com South Africa
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial - HCPLive
Cognition Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - Santé log
Ratio Examination: Cognition Therapeutics Inc (CGTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire
Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider
Cognition Therapeutics, Inc. Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - marketscreener.com
Cognition Therapeutics (CGTX) Stock Target Lowered by Chardan Ca - GuruFocus
COGNITION THERAPEUTICS INC SEC 10-Q Report - TradingView
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - The Manila Times
Cognition Therapeutics, Inc. Advances Alzheimer’s and DLB Programs with FDA Meeting Request and Upcoming Presentations at AAIC and ARVO - Nasdaq
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides ... - Bluefield Daily Telegraph
Caregiver Distress The Hidden Burden Of Dementia With Lewy Bodies — And Why Measuring It Matters - Clinical Leader
Geode Capital Management LLC Raises Holdings in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
CES ENERGY SOLUTIONS CORP. ANNOUNCES AMENDMENT AND EXTENSION TO ITS INCREASED CREDIT FACILITY - The Globe and Mail
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cognition Therapeutics Inc [CGTX] Shares Fall Approximately -76.27% Over the Year - knoxdaily.com
Cognition Therapeutics Inc (CGTX) Stock: Navigating a Year of Volatility - investchronicle.com
CGTX Stock Sees Surge of Approximately 16.59% in Last Five Days - knoxdaily.com
Dry AMD Therapeutics Market Size in 7MM is expected to grow at - openPR.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN
Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com
2025 Is Shaping Up To Be A Big Year For This Drug Maker Working To Cure Dementia - Benzinga
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):